I N T R O D U C T I O N
The annual incidence of rheumatoid arthritis (RA) has been reported to be nearly 40/100 000. The disease prevalence is $1% in Caucasians, but varies between 0.1 and 5% [1, 2] . Women are affected by RA two to three times more often than men [3] . RA is one of the chronic inflammatory diseases, and the main inflammatory site for RA is the articular synovium. The pathogenesis of RA is not fully understood, yet both genetic susceptibility in hosts and interactions of multiple innate and acquired immune cells are possibly involved [4] [5] [6] . The paradigm for RA therapy has greatly changed over the past decade. In addition to synthetic disease-modifying anti-rheumatic drugs (DMARDs), such as methotrexate (MTX), there are also biologic DMARDs that selectively target cytokines, including tumor necrosis factor (TNF) and interleukin-6 (IL-6), and/or those cytokine receptors in the cells [7] [8] [9] [10] . Although the use of these new therapeutic agents has improved the prognosis of RA, this disease still remains a great risk for serious chronic diseases such as lung disease, cardiac disease, noncardiac vascular disease, nervous system involvement, hematologic abnormality and kidney disease [11, 12] .
RA is known to be associated with several kidney disorders. Multiple factors related to chronic inflammation and cumulative exposure to some nephrotoxic agents are most likely associated with the development of kidney insults. Previous studies have shown that membranoproliferative glomerulonephritis is the most frequent renal disease of RA patients, the prevalence of which was reported to be 34-36% in renal biopsy specimens. In addition, membranous nephropathy is the second most frequent, ranging from 17 to 31%. Interstitial nephritis, pauci-immune glomerulonephritis and amyloidosis are also common renal histological lesions in RA patients [13, 14] . The intrinsic glomerulotubular disease progresses to renal function decline.
Chronic kidney disease (CKD) is now considered one of the most important public health problems, as it is closely associated with high mortality and the development of end-stage renal disease (ESRD) and cardiovascular disease (CVD) in the general population globally [15] . Although many adverse impacts of CKD on RA patients are assumed, only a few studies have been published up to now. These studies show that the prevalence of renal dysfunction among RA patients varies from 5 to 50% [12] [13] [14] [16] [17] [18] [19] . However, these data were based on the former CKD classification of the 2002 National Kidney Foundation-Kidney Disease Outcomes Quality Initiative (NKF-KDOQI), which used only stages of estimated glomerular filtration rate (eGFR). The former KDOQI CKD classification proved incomplete, as it lacked the significant impact of proteinuria or albuminuria on renal and overall prognosis [15, 20] . Consequently, the updated CKD classification, which comprised both the staging of eGFR and grading of albuminuria, was published as the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline in 2012 [21] . This new classification elaborated on the identification and severity of CKD with four risk categories. To the best of our knowledge, there have been no reports studying the prevalence of CKD among RA patients according to the 2012 KDIGO CKD classification, which is hereafter denoted as the current CKD classification. Moreover, the incidence of CKD over time has not been fully understood in RA patients. There is only one study showing that the cumulative incidence of CKD was 15% at 10 years and 25% at 20 years; nevertheless, the study was based on eGFR, taking no account of proteinuria or albuminuria [12] .
The main objectives of this study are (i) to clarify the prevalence of CKD and its contribution to mortality, and (ii) to examine the cumulative incidence of CKD over time and the factors associated with incident CKD. CKD was identified according to the current CKD classification using data accumulated over 10 years in a single tertiary hospital for RA.
M A T E R I A L S A N D M E T H O D S

Study design
This was a retrospective cohort study in RA patients. RA was defined based on the 1987 American College of Rheumatology criteria for the classification of RA [22] . The study was performed in accordance with the Declaration of Helsinki and approved by the institutional committee on research ethics (approval certificate no. 1680).
Study population
A total of 1595 RA patients who regularly visited the Division of Collagen Disease, Department of Medicine Tokyo Metropolitan Komagome Hospital were enrolled in the study. The exclusion criteria at entry were as follows: those with less than three visits, follow-up period <3 months, age <20 years, lacking at least two consecutive sets of laboratory data, having other systemic autoimmune diseases and manifesting acute renal failure. Finally, 1077 RA patients were eligible for analysis.
Data collection
Demographics and laboratory data that were accumulated in the electronic medical charts were longitudinally followed from 1 July 2004 to 30 June 2014. The following demographic and laboratory data were obtained from all participants: age; gender; RA duration; the presence of comorbidities, including diabetes mellitus (DM), hypertension (HT), malignancy, cerebral vascular disease, CVD comprising ischemic heart disease (IHD), peripheral arterial disease, atrial fibrillation, chronic heart failure, bronchial asthma, interstitial pneumonia (IP) and other systemic autoimmune diseases; urine dipstick test; ESR; hemoglobin (Hb); hemoglobin A1c and serum concentrations of creatinine (Cr), albumin (Alb), uric acid (UA), C-reactive protein (CRP), rheumatoid factor (RF), anti-cyclic citrullinated peptide antibody, matrix metalloproteinase-3 and ferritin. DM was defined as a diagnosis of DM prior to baseline or the use of oral antidiabetic agents or insulin at baseline. Hypertension should be replaced by HT. was defined as a systolic blood pressure !140 mmHg and/or diastolic blood pressure !90 mmHg or the use of antihypertensive agents at baseline. IHD included myocardial infarction, angina pectoris and a past history of revascularization procedures. Cerebral vascular disease included cerebral hemorrhage and infarction. In addition, the presence or absence of use of the following drugs was determined: systemic steroids [prednisolone (PSL)], synthetic DMARDs (MTX, sulfasalazine, actarit, bucillamine, D-penicillamine, gold, tacrolimus, mizoribine, azathioprine and leflunomide), biologic DMARDs (infliximab, etanercept, adalimumab, tocilizumab and abatacept), proton pump inhibitors, calcium channel blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and nonsteroidal anti-inflammatory drugs (NSAIDs).
Measurements and definitions
Proteinuria was defined as !1þ on urine dipstick examination. eGFR was calculated on the basis of serum Cr using the three-variable Japanese equation constructed by the Japanese Society of Nephrology: eGFR (mL/min/1.73 m . The prevalence of CKD at enrollment was evaluated according to the current CKD classification. In brief, the participants were distributed into a 6 Â 3 table, combining eGFR with proteinuria (e.g. G3bA2). CKD was defined as either eGFR <60 mL/min/1.73m 2 or proteinuria !1þ or both that were sustained at least for 3 months, and the severity of CKD was classified into the following four categories: no risk (non-CKD) (G1A1 and G2A1), moderate risk (G1A2, G2A2 and G3aA1), high risk (G1A3, G2A3, G3aA2 and G3bA1) and very high risk (G3aA3, G3bA2, G3bA3, G4 and G5) [21] . 2036 T. Tokoroyama et al.
Data were shown as mean 6 standard deviation (SD) unless otherwise stated. Two patient groups were compared using the Mann-Whitney U-test for continuous variables and the Fisher exact test for categorical variables. The cumulative mortality over time was estimated with the Kaplan-Meier method, and the statistical significance between two groups was compared by the log-rank test. The cumulative incidence of CKD was estimated and compared using Kaplan-Meier analysis in the subcohort with no prior CKD at entry. The association of prevalent CKD with mortality over time was analyzed using a Cox multivariate proportional hazards regression model, adjusted for the following known risk factors: age, gender, RA duration, presence and absence of DM, HT, malignancy, CVD, cerebral vascular disease, IP and the use of PSL. Furthermore, a Cox multivariate proportional hazards regression model was used to identify factors associated with the incidence of CKD, incorporating the following covariates: age; gender; RA duration, presence and absence of DM, HT, CVD, cerebral vascular disease, IP; Hb, Alb, UA, CRP and the use of PSL, NSAIDs and DMARDs. Hazard ratios (HRs) with their 95% confidence intervals (CIs) for mortality and incidence of CKD were calculated in multivariate analyses. All statistical analyses were performed using software for statistics, JMP version 12.0 (SAS Institute Japan, Tokyo, Japan) and EZR, which is a graphical user interface for R (version 2.13.0; R Foundation for Statistical Computing, Vienna, Austria) [24] . P-values <0.05 were considered significant.
R E S U L T S
Prevalence of CKD in RA
Of 1595 RA patients who regularly visited our hospital, 1077 patients were enrolled. A total of 518 patients were excluded, as their age was <20 years, 109 lacked the required two consecutive data, 371 possibly had other systemic autoimmune diseases and 19 manifested acute renal failure. Demographics and baseline laboratory data for 1077 RA patients, stratified by the presence or absence of CKD, are presented in Table 1 . The study cohort included 246 (22.8%) men, and the mean age was 63.8 6 12.9 years. The mean RA duration from the diagnosis to enrollment was 67.3 6 101.6 months (range 1-730 months). The prevalence of CKD was significantly higher in men than in women (30.7 versus 20.3%; P < 0.001). Additionally, the CKD patients had a higher likelihood of anemia, hyperuricemia, hypoalbuminemia, HT, DM, CVD and IP. The distribution of preexisting CKD in RA patients is shown in Table 2 . A total of 222 patients (20.6%) had eGFR <60 mL/min/1.73 m 2 , 86 (7.99%) proteinuria and 44 (4.09%) both. Therefore, 264 (24.5%) patients were affected by CKD at enrollment, according to the current CKD classification: 813 (75.5%) with no risk (non-CKD; G1A1 and G2A1; white color), 160 (14.9%) with moderate risk (G1A2, G2A2, G3aA1; light gray color), 63 (5.85%) with high risk (G1A3, G2A3, G3aA2, G3bA1; medium gray color) and 41 (3.81%) with very high risk (G3aA3, G3bA2, 3, G4A1-3, G5A1-3; dark gray color).
Influence of prevalent CKD on mortality
During the follow-up of 51. 5 Table 3) .
Incidence of CKD and its relevant factors
A subanalysis was performed to examine the incidence of CKD in 813 patients with no prior CKD and 854 patients with eGFR !60 mL/min/1.73 m 2 at baseline. In the follow-up period, 260 of 813 patients (31.9%) developed new CKD and 205 of 854 (25.2%) showed a persistent decrease in eGFR <60 mL/min/ 1.73 m 2 (renal dysfunction). The incidence of CKD and renal dysfunction were 74.70/1000 person-years and 56.49/1000 person-years, respectively. For both, the cumulative incidences over 10 years are shown in Figure 2 using Kaplan-Meier curves. The 10-year cumulative incidence of CKD and renal dysfunction was 62.5 and 49.9%, respectively. As shown in Figure 3 , factors associated with the incidence of CKD were examined using a multivariate Cox proportional hazards regression model, adjusted for potential covariates for CKD. Higher age [HR The prevalence, incidence and prognosis of CKD were evaluated according to the current CKD classification with risk categories in the RA patients who were regularly followed up by RA experts in a single tertiary hospital in Japan. The prevalence of CKD was nearly one-quarter of the cohort, and the preexisting CKD, particularly very-high risk, was an increased risk correlated with all-cause mortality. Moreover, the cumulative incidence of CKD was $60% in the non-CKD subcohort at 10 years after study initiation. Older men with DM, HT and exposure to NSAIDs were predisposed to incident CKD. This is the first study that clarified the prevalence of CKD among RA patients (24.5%) on the basis of combined eGFR and proteinuria data according to the current CKD classification. Numerous studies of CKD have determined that sustained proteinuria or albuminuria is one of the most reliable biomarkers for early identification of CKD, and also that it, per se, is a harbinger of poor prognosis, such as ESRD, CVD, and death, in the general population [21] . Therefore, the 2012 KDIGO updated the 2002 KDOQI guideline for CKD and elaborated on the identification and prognosis of CKD by combining eGFR with albuminuria. There were no prior reports to test the prevalence of CKD among RA patients, according to the current CKD classification, although RA patients may have higher risk of renal Data are expressed as mean 6 standard deviation. P-value indicates the difference between CKD and non-CKD. CKD, chronic kidney disease; BMI, body mass index; eGFR, estimated glomerular filtration rate; Hb, hemoglobin; UA, uric acid; CRP, C-reactive protein; MMP-3, matrix metalloproteinase-3; CCP, cyclic citrullinated peptide; IHD, ischemic heart disease; CHF, chronic heart failure; PPI, proton pump inhibitor; CCB, calcium channel blocker; ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker. Cardiovascular disease includes IHD and CHF. Other synthetic DMARDs include D-penicillamine, mizoribine, azathioprine and leflunomide. Biologic DMARDs include infliximab, etanercept, adalimumab, tocilizumab and abatacept. [12] . Indeed, a few previous studies attempted to address this topic of clinical interest [16, 17, 25] ; however, the data were inadequate from the point of view of the current CKD concept, as they showed neither data combining eGFR with proteinuria or albuminuria nor confirmation of the persistence of kidney disease for !3 months. The prevalence of any CKD among 103.2 million Japanese adults from the general population was 13.3 million (12.9%), according to the statistics provided by the Japan Ministry of Health, Labour and Welfare in 2012 [26] . In addition, the National Health and Nutrition Examination Survey (NHANES) conducted by the National Center for Health Statistics (NCHS) showed that the prevalence of CKD among the general adult population in the USA was 13.3%, based on the current CKD classification [27] . These comparisons suggest that the frequency of CKD might be 2-fold higher in the RA population than in the adult general population. However, De Broe et al. [28] reported that choice of the arbitrary single threshold of eGFR for classifying CKD, i.e. an eGFR <60 mL/min/1.73 m 2 , leads to 'overdiagnosis' in the elderly and 'underdiagnosis' in young individuals. In our RA subjects, whose mean age was 63.8 years, the prevalence of CKD may be overestimated. Further examinations for prevalence according to the current CKD classification in the general population across countries will be warranted to determine whether the prevalence of CKD in RA is elevated or not.
FIGURE 1: Comparisons of cumulative mortality over time among RA patients. The Kaplan-Meier curves are drawn over 10 years, stratified by the presence or absence of any CKD. The difference between the curves was analyzed with the log-rank test. An asterisk (*) indicates that the difference between any CKD and non-CKD is significant (P < 0.001). Chronic kidney disease (CKD; solid line), non-CKD (dashed line) and overall patients (dotted line). CKD was classified into the following four categories: no risk (G1A1 and G2A1), moderate risk (G1A2, G2A2 and G3aA1), high risk (G1A3, G2A3, G3aA2 and G3bA1) and very high risk (G3aA3, G3bA2, G3bA3, G4 and G5). The multivariate analyses were conducted for either any CKD or each CKD category, adjusted for age, gender, RA duration, presence or absence of diabetes mellitus, hypertension, malignancy, cardiovascular disease, cerebral vascular disease, interstitial pneumonia and use of drugs including prednisolone, NSAIDs and DMARDs. Age, cardiovascular disease, malignancy, diabetes mellitus, interstitial pneumonia and use of prednisolone were significantly involved. Their HRs (95% CIs) are described in the Results section. HR, hazard ratio; CKD, chronic kidney disease. CKD was defined as either eGFR <60 ml/min/1.73 m 2 or proteinuria !1þ, or both, and the severity of CKD was classified into the following four categories: no risk (non-CKD; G1A1 and G2A1; white color), moderate risk (G1A2, G2A2 and G3aA1; light gray color), high risk (G1A3, G2A3, G3aA2 and G3bA1; medium gray color) and very high risk (G3aA3, G3bA2, G3bA3, G4 and G5; dark gray color). Among 1077 RA patients, the percentages with non-CKD, any CKD and severe (high to very high risk) CKD were 75.5, 24.5 and 9.5%, respectively. RA patients with CKD may be at higher risk for death. Our longitudinal study clarified that preexisting CKD was significantly associated with mortality and that, in the more detailed analysis, only the very-high-risk category increased the likelihood of mortality as compared with the no-risk category. This suggests that not only the identification but also the assessment of risk category, based on the current CKD classification, is of special relevance to predict the outcomes of RA patients. Moreover, aside from the commonly known risk factors, including higher age, DM, cancer, IP and CVD, the use of PSL was a significant risk factor associated with mortality. Indeed, Mikulus et al. [29] and Jacobsson et al. [30] previously reported FIGURE 3: Factors associated with the incidence of CKD in RA. Multivariate analysis was conducted to identify factors associated with the incidence of CKD, incorporating the covariates shown in the figure. that the use of glucocorticoids was significantly related to the mortality of RA patients, possibly because their use seemed to reflect that the patients were affected by refractory RA that manifested a poor response to the common RA therapies. In addition, glucocorticoids, per se, have some detrimental side effects associated with increased risk for dyslipidemia, HT and immunodeficiency, which may contribute to the development of atherosclerotic diseases and intractable infections. These factors may in part account for the increased mortality in the recipients of PSL. Unfortunately, this study did not clarify correlations between the duration of PSL therapy and mortality. In addition, our study did not show that the use of synthetic and biologic DMARDs affects mortality.
How often do RA patients develop new CKD during the follow-up period? Our study showed that one-third of the RA patients developed new CKD and one-quarter of them developed renal dysfunction in the follow-up period. There were a few previous reports that assessed the incidence of renal dysfunction among RA patients. In a longitudinal study, Hickson et al. [12] showed that the cumulative incidence of renal dysfunction was 25.1% over 20 years among 739 RA patients without prior eGFR <60 mL/min/1.73 m 2 . Thus, our cumulative incidence of renal dysfunction (46.6%) was higher than that. It could possibly be because our study cohort was >8 years older (63.8 6 12.9 versus 55.9 6 15.7 years) and had a nearly 2-fold higher proportion of DM (17.4 versus 9.7%). Furthermore, there may be some selection bias due to the inclusion criteria. Our cohort comprised those who required consecutive laboratory data follow-up, possibly due to some medical problems, which may be associated with an elevation of the incidence of CKD. At present, except for our current study, we could find none referring to the incidence of CKD determined by a combination of eGFR and proteinuria, as proposed by the current CKD classification.
This study suggested several factors associated with the incidence of CKD in RA. First, the cumulative exposure to NSAIDs was relevant, as shown in a few preceding studies [12, 31] . Burkhard et al. [32] reported that the use of NSAIDs was an independent predictor for accelerated renal function decline in RA patients with advanced baseline renal impairment (eGFR <30 mL/min/1.73 m 2 ) by using multivariate Cox regression analysis, although the impact of NSAID use on eGFR decrease among patients without renal impairment was uncertain. Our multivariate Cox proportional hazards regression model indicated that exposure to NSAIDs was significantly associated with incident CKD. However, we did not test the relationship between CKD incidence and either the total amount or duration of NSAIDs given, as such data were not fully obtained. The nephrotoxicity of NSAIDs is well recognized, and thus avoiding excessive administration of NSAIDs and routine monitoring for kidney disease are always required for prevention and early identification of kidney insults, especially in RA recipients of NSAIDs who have concurrent risk factors for incident CKD. Older age, HT and DM were associated with the incidence of CKD, as these factors are known to have a significant impact on athero-/arteriosclerosis of small vessels in the kidney, contributing to kidney function decline [33] . In addition, men were at increased risk for incident CKD, which may suggest that men could be more predisposed to kidney disease than women, possibly because men have a higher likelihood of having DM and HT due to poor daily habits, such as heavy smoking and drinking.
This was a population-based study conducted in a relatively large RA cohort having adequate data for combining eGFR with proteinuria, which likely allowed for the accurate assessment of CKD in RA. Nonetheless, there were several limitations in this study. First, the statistical power may not be robust in determining the incidence of CKD and its relevant factors due to the retrospective cohort design of the study. Second, the study population was limited to urban Japanese who were regularly followed up by RA specialists in a single tertiary hospital, which may indicate that these patients tend to have refractory RA, comorbidities to be treated and almost similar socioeconomic conditions. Therefore, our cohort may not be representative of the Japanese RA population and our results may not be generalizable to other ethnic populations. Third, our study was undertaken on the basis that dipstick proteinuria could be utilized as a convenient alternative to albuminuria, and therefore our method differed from the original 2012 KDIGO classification in which albuminuria was used. Although albuminuria would be expected to be more accurate for evaluating kidney glomerular damage and prognosis than dipstick proteinuria, it is more expensive and not readily applicable for use in a general clinical setting from the perspective of the health insurance system. In addition, recent studies have validated that proteinuria and albuminuria perform equally well as predictors of renal outcomes and mortality in patients with CKD [34] .
In conclusion, based on the current CKD classification with risk categories for future adverse outcomes, we characterized CKD in a large cohort of RA patients. Prevalent CKD is a risk factor linked with mortality, and the incidence of CKD increases over time in RA. Our study alerts RA experts that CKD is one of the critical comorbidities, as it may contribute to a poor prognosis for RA patients. More studies on CKD across countries, based on the current CKD classification, are warranted to accumulate evidence about this issue, perhaps leading to improvement of health care for RA patients.
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